Finasteride for Health & Longevity
Evidence Review created on 11/06/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Propecia, Proscar, Finpecia, MK-906
Motivation
Finasteride (Propecia, Proscar) is a prescription oral medication that blocks the body’s conversion of testosterone into a stronger hormone that drives prostate growth and pattern hair loss. It is widely prescribed to older men and draws interest from longevity-focused adults because it acts on two common age-related concerns: an enlarging prostate and prostate cancer risk.
Finasteride was first approved in the early 1990s for an enlarged prostate and later, at a lower dose, for male pattern hair loss. A very large prevention study then tested whether years of daily use could lower the chance of developing prostate cancer, and decades of follow-up have kept that question open. Meanwhile, reports of sexual and mood changes, some lasting after the drug is stopped, have made it one of the most debated medications in men’s health.
This review examines the evidence for and against finasteride as a long-term health and longevity tool for adults willing to manage a prescription drug closely. It covers prostate, hair and cancer outcomes, the full range of reported harms, how dose and form matter, and the monitoring that published protocols describe.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Expert discussions and a narrative review that give a high-level overview of finasteride’s uses, benefits and controversies.
-
Hair-loss drug finasteride repeatedly linked to depression and suicidal thoughts - FoundMyFitness
A Science Digest summary of a review of eight adverse-event-database and national-registry studies, all reporting higher depression, anxiety, self-harm or suicide rates among finasteride users, citing lowered brain-acting steroids as the proposed mechanism.
-
#273 ‒ Prostate health: common problems, cancer prevention, screening, treatment, and more – Ted Schaeffer, M.D., Ph.D. - Peter Attia
A urologist interview covering finasteride for prostate shrinkage and hair loss, the disputed post-finasteride syndrome (symptoms persisting after stopping), and PSA (prostate-specific antigen, a blood marker for prostate cancer) screening.
-
The Science of Healthy Hair, Hair Loss and How to Regrow Hair - Andrew Huberman
A hair-biology episode with segments on oral and topical finasteride, dutasteride and post-finasteride syndrome, explaining why lowering DHT (dihydrotestosterone, a potent male hormone) slows hair loss.
-
The Avodart® - Proscar® Debate - William Faloon
Argues from the large prostate-cancer prevention trials that the apparent excess of high-grade tumors reflects grading and detection bias, giving a clear statement of the pro-prevention position.
-
Post-finasteride syndrome - a true clinical entity? - Cilio et al., 2025
A urology narrative review weighing evidence for and against post-finasteride syndrome as a distinct condition, including proposed neurobiological and genetic mechanisms and the dispute over its recognition.
No directly relevant content was found from Chris Kresser (chriskresser.com) or Lifespan.io: both on-site searches and web searches returned no finasteride material.
Grokipedia
A machine-written encyclopedia entry summarizing finasteride’s chemistry, approved uses, pharmacology and controversies; useful for quick orientation, though its claims need checking against primary sources.
Examine
No dedicated Examine article on finasteride exists; the site search returns only a members-only research-feed summary on depression and suicidal ideation. Examine.com does not typically cover prescription medications.
ConsumerLab
No dedicated ConsumerLab article on finasteride exists; the drug appears only within its hair-loss and prostate-supplement pages. ConsumerLab does not typically cover prescription medications.
Systematic Reviews
Systematic reviews and meta-analyses covering finasteride’s main benefits and its principal risks.
-
Finasteride for benign prostatic hyperplasia - Tacklind et al., 2010
Cochrane review: finasteride improves long-term urinary symptoms and lowers progression risk in BPH (benign prostatic hyperplasia, noncancerous prostate enlargement) but increases sexual side effects.
-
Five-alpha-reductase Inhibitors for prostate cancer prevention - Wilt et al., 2008
Cochrane review: 5α-reductase inhibitors (drugs blocking testosterone-to-DHT conversion) cut detected prostate cancer by about a quarter, with more high-grade tumors; mortality data were inadequate.
-
Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review - Mella et al., 2010
Twelve RCTs (randomized controlled trials) in 3,927 men with androgenetic alopecia (hereditary pattern hair loss): hair counts and appearance improved, with excess erectile dysfunction.
-
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis - Lee et al., 2019
Fifteen placebo-controlled trials: finasteride 1 mg raised sexual dysfunction risk 1.66-fold, quantifying the main trade-off of hair-loss use.
-
Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis - Uleri et al., 2024
Five observational studies, over two million men: no statistically significant association with depression or suicide, contrasting with individual cohort signals.
Mechanism of Action
Finasteride is a synthetic 4-azasteroid (steroid-like molecule) that competitively inhibits type II 5α-reductase, the enzyme converting testosterone to DHT in the prostate, seminal vesicles, hair follicles and liver (Propecia label). It is about 100-fold more selective for type II than for type I, the skin and liver form that produces roughly one-third of circulating DHT, so DHT suppression is partial: about 65% within 24 hours at 1 mg (same label) and 73% at 5 mg (Amory 2007). Testosterone and estradiol rise about 15% but stay within physiological ranges.
- Prostate: lower DHT shrinks the gland by about 20% and halves PSA, per a pharmacology review (Steiner 1996).
- Scalp: lower follicular DHT halts miniaturization (progressive shrinking of hair follicles) in genetically susceptible men.
- Brain: finasteride crosses the blood–brain barrier and blocks formation of neuroactive steroids (brain-acting hormone metabolites such as allopregnanolone) from progesterone (Godar 2019), the leading, contested explanation for mood and persistent effects, per a review (Cilio 2025).
- Competing cancer explanations: lower DHT may slow prostate cancer development, or smaller glands may make biopsies detect tumors more easily (Redman 2008).
Pharmacology: oral bioavailability (share of a dose reaching the blood) about 65%, 90% protein-bound, metabolized in the liver mainly by CYP3A4 (a liver enzyme that breaks down many drugs) to weakly active metabolites excreted in feces and urine. Plasma half-life is 5–6 hours (8 hours after age 70), but the enzyme–drug complex turns over in about 30 days, so DHT suppression outlasts plasma levels (Propecia label).
Historical Context & Evolution
Finasteride traces to studies of men with inherited 5α-reductase deficiency, whose low DHT caused incomplete genital masculinization before birth yet marked virilization (development of male features) at puberty (Imperato-McGinley 1974). This pointed to DHT as a target that could be blocked selectively. Merck developed the compound as MK-906; the FDA (U.S. Food and Drug Administration) approved Proscar 5 mg for BPH in June 1992 and Propecia 1 mg for male pattern hair loss in December 1997 (FDA topical finasteride alert).
Interest for health optimization grew along three lines:
- Cancer prevention: the publicly funded PCPT found fewer prostate cancers but more high-grade tumors (Thompson 2003); the high-grade finding produced a class label warning, and Proscar is not approved for prevention (Proscar label).
- Reinterpretation: bias-adjusted reanalyses (Redman 2008), 18-year survival data (Thompson 2013) and mortality follow-up (Goodman 2019) moved the debate from feared harm toward a neutral reading; the original counts stand, but their meaning is disputed.
- Safety re-evaluation: postmarketing reports added persistent sexual dysfunction, depression and suicidal ideation to the label (Propecia label); a survey of former users with persistent sexual symptoms then found frequent depressive symptoms and suicidal thoughts (Irwig 2012); and, in 2025, the EMA (European Medicines Agency) confirmed suicidal ideation as a side effect (EMA referral).
Each new data set has shifted opinion in a different direction; neither the prevention question nor the persistent-harm question is closed.
Expected Benefits
High 🟩 🟩 🟩
Fewer Prostate Enlargement Complications and Surgeries
In men with symptomatic BPH, finasteride 5 mg shrinks the prostate and lowers long-term risk of AUR (acute urinary retention, sudden inability to urinate) and surgery. This was shown in the PLESS trial, sponsored by the manufacturer Merck (McConnell 1998), the National Institutes of Health–funded MTOPS trial (McConnell 2003), and a Cochrane review pooling trials from several groups (Tacklind 2010). Symptom gains are small and smaller than with the alpha-blockers (drugs relaxing prostate and bladder-neck muscle) doxazosin or terazosin.
Magnitude: Over 4 years, AUR occurred in 3% vs 7% with placebo, a 57% risk reduction with a 95% CI (confidence interval, the range likely holding the true value) of 40–69%, and surgery in 5% vs 10%, a 55% risk reduction (95% CI 41–65%) (McConnell 1998).
Slowed Pattern Hair Loss and Regrowth ⭕️ Not Central to Health & Longevity ⚠️ Conflicted
Finasteride 1 mg lowers scalp DHT and slows follicle miniaturization in androgenetic alopecia. In men, Merck-sponsored trials (Kaufman 1998), an independent meta-analysis of 12 RCTs (Mella 2010) and an Almirall-sponsored topical trial (Piraccini 2022) agree; the benefit bears on appearance, not lifespan, and reverses within 12 months of stopping (Propecia label). In women, a systematic review reported recovery mainly with 5 mg (Nobari 2023), but a Merck-sponsored placebo-controlled 1 mg trial after menopause found none (Price 2000). Net: replicated benefit in men, unconfirmed by placebo control in women.
Magnitude: 138 more hairs than placebo in a 5.1 cm² vertex area at 2 years (Kaufman 1998); long-term hair count 24.3% higher than placebo (95% CI 17.9–30.6%), NNT (number needed to treat for one additional man to perceive improvement) 3.4 (Mella 2010); in postmenopausal women, no significant hair-count difference versus placebo after 1 year at 1 mg (Price 2000).
Less Prostate-Related Bleeding ⚠️ Conflicted
Finasteride lowers prostate blood-vessel density, reducing bleeding from an enlarged gland. Placebo-controlled trials by Donohue’s UK group (Donohue 2002) and Bansal’s Indian group (Bansal 2017) found less blood loss during prostate surgery after 2–4 weeks of 5 mg, and a meta-analysis of 17 RCTs agreed (Zhu 2015); a smaller Swedish trial found no overall difference (Sandfeldt 2001). Net: pooled trials favor a reduction that the null trial does not outweigh.
Magnitude: Hematuria (blood in the urine) over 12 months less frequent than with placebo (OR (odds ratio, how much the odds of an event change versus the comparison group) 0.11, 95% CI 0.06–0.21) in a meta-analysis (Jiang 2010); blood transfusion during surgery in 2.7% vs 9.3% with placebo (Bansal 2017).
Reduced Hirsutism in Women ⭕️ Not Central to Health & Longevity ⚠️ Conflicted
By lowering follicular DHT, finasteride 5 mg reduced hirsutism (excess male-pattern hair growth in women) in placebo-controlled trials by Moghetti’s Verona group (Moghetti 2000) and Lakryc’s São Paulo group (Lakryc 2003); a 43-trial network meta-analysis (comparing many treatments at once) found it similar to spironolactone (Barrionuevo 2018), while a Cochrane review judged the evidence very low quality (van Zuuren 2015). It bears on cosmetic and polycystic-ovary symptoms, not longevity, and is contraindicated in pregnancy (Propecia label). Net: replicated trials show a reduction Cochrane judged unlikely to be clinically meaningful.
Magnitude: Ferriman-Gallwey hirsutism score 5.73 points lower than placebo (95% CI −6.87 to −4.58), very low-quality evidence (van Zuuren 2015).
Medium 🟩 🟩
Fewer Prostate Cancer Diagnoses
Lower prostate DHT may slow androgen-dependent tumor development. In the National Cancer Institute–funded PCPT, 18,882 men aged 55 or older with PSA ≤3.0 ng/mL took 5 mg daily or placebo for 7 years; finasteride reduced cancers, mainly low-grade (Thompson 2003). Medicare-linked follow-up by the same SWOG cancer research group to 16 years showed no later catch-up (Unger 2018). A Cochrane review notes that only the PCPT was designed to test prevention (Wilt 2008). Fewer diagnoses mean fewer biopsies and treatments, not by themselves longer survival.
Magnitude: 7-year prevalence 18.4% vs 24.4% with placebo (24.8% relative reduction, 95% CI 18.6–30.6%) (Thompson 2003); 18-year diagnoses 10.5% vs 14.9%, RR (relative risk, the event rate on finasteride divided by the rate on placebo) 0.70 with 95% CI 0.65–0.76 (Thompson 2013).
Lower Bladder Cancer Incidence ⚠️ Conflicted
Lower DHT may slow androgen-driven bladder tumor growth. A meta-analysis of observational studies found fewer bladder cancers with finasteride (Yu 2025), consistent with a U.S. screening-trial cohort (Morales 2016) and an Ontario cohort after 2 or more years of use (Dekalo 2023). A secondary analysis of the randomized MTOPS arms found no difference but recorded only 18 cases (Sathianathen 2018). Net: a consistent observational signal that the one small randomized analysis can neither confirm nor refute.
Magnitude: Bladder cancer HR (hazard ratio, the relative event rate over time) 0.75 (95% CI 0.63–0.88) with finasteride versus non-use, pooled from observational studies (Yu 2025); 0.74% vs 0.61% in the MTOPS randomized arms, not significant (Sathianathen 2018).
Low 🟩
Prostate Cancer Death and Overall Survival ⚠️ Conflicted
PCPT follow-up recorded fewer prostate cancer deaths with finasteride, but the difference was not statistically significant (Goodman 2019), and 15-year overall survival was unchanged (Thompson 2013). Net: no demonstrated survival benefit, and no survival harm.
Magnitude: 42 vs 56 prostate cancer deaths, HR 0.75 with 95% CI 0.50–1.12, not significant (Goodman 2019); death from any cause HR 1.02 (95% CI 0.97–1.08) (Thompson 2013).
Prostate Protection During Testosterone Therapy
In two RCTs of older men with low testosterone, adding finasteride 5 mg to testosterone injections prevented (Borst 2014) or reduced (Amory 2004) testosterone-driven prostate growth while preserving strength and bone gains. Evidence is indirect: finasteride was tested only together with testosterone.
Magnitude: Testosterone enlarged the prostate by 11.4 cm³ over 12 months, an effect completely prevented by finasteride (Borst 2014).
Improved Hidradenitis Suppurativa ⭕️ Not Central to Health & Longevity
Hidradenitis suppurativa (a chronic inflammatory skin disease with painful nodules and abscesses) may respond to lower androgen activity. A systematic review of mostly uncontrolled reports found improvement in most finasteride-treated patients with recorded outcomes (Masson 2023). The benefit bears on skin disease, not longevity.
Magnitude: 27 of 43 finasteride-treated patients with reported outcomes (62.8%) improved (no control group) (Masson 2023).
Stabilized Frontal Fibrosing Alopecia ⭕️ Not Central to Health & Longevity
Frontal fibrosing alopecia (scarring loss of the frontal hairline, mostly in postmenopausal women) may respond to lower androgen activity. A systematic review of uncontrolled reports found oral 5α-reductase inhibitors the most effective option (Rácz 2013). Evidence is indirect: results pool finasteride with dutasteride. It bears on hair, not longevity.
Magnitude: Good clinical response in 45% of patients treated with oral 5α-reductase inhibitors (no control group) (Rácz 2013).
Speculative 🟨
No benefit is graded Speculative: no animal lifespan study or other preclinical aging data for finasteride were identified.
Benefit-Modifying Factors
- Genetic variation: Variants in SRD5A2 (the gene encoding type II 5α-reductase) and other steroid-metabolizing genes are proposed, per a review, to explain wide individual differences in response; no genotype test predicts benefit in practice (Hulin-Curtis 2010).
- Baseline PSA: Reductions in detected prostate cancer were seen in men with baseline PSA below 4.0 ng/mL, but not above it, per a Cochrane review (Wilt 2008).
- Prostate size: Adding finasteride to doxazosin improved urinary symptoms only in men with prostates of at least 25 mL, per a Cochrane review (Tacklind 2010).
- Sex: Finasteride 1 mg did not slow hair thinning in postmenopausal women (Price 2000), whereas hirsutism does respond in a network meta-analysis (Barrionuevo 2018); the hair-loss approval covers men only (Propecia label).
- Hair-loss pattern: Trials measured crown regrowth; efficacy in bitemporal recession (receding temples) has not been established (Propecia label).
- Age: Hair trials enrolled men aged 18–41, and hair efficacy over 65 is unestablished (Propecia label); prostate benefits were shown in men aged 45–78 in PLESS (Proscar label) and 55 or older in PCPT (Thompson 2003).
- Testosterone therapy: In men aged 60 or older with low testosterone on TRT (testosterone replacement therapy), adding finasteride prevented prostate growth without losing muscle, fat-loss or bone benefits (Borst 2014).
Potential Risks & Side Effects
High 🟥 🟥 🟥
Sexual Dysfunction During Use ⚠️ Conflicted
Lowering DHT can reduce libido, erectile function and ejaculation. Excess rates appear in Merck-sponsored trials (Kaufman 1998; McConnell 1998), the publicly funded PCPT (Thompson 2003), and independent meta-analyses (Mella 2010; Lee 2019); per the label, events resolved in men who stopped and in most who continued. An earlier meta-analysis found no significant excess in men treated for hair loss (RR 1.21, 95% CI 0.85–1.72), only with BPH (Liu 2016). Net: a real excess, clearest at 5 mg and also shown at 1 mg by a later 15-trial pooled analysis.
Magnitude: In 1 mg trials, one or more sexual adverse events in 3.8% vs 2.1% with placebo; with 5 mg, first-year impotence in 8.1% vs 3.7% (Propecia label); erectile dysfunction RR 2.22 vs placebo (95% CI 1.03–4.78), NNH (number needed to harm, how many men must be treated for one extra man to have the effect) 82 (Mella 2010).
Medium 🟥 🟥
High-Grade Prostate Cancer ⚠️ Conflicted
The PCPT found more tumors with Gleason scores of 7–10 (a pathology grade where higher means more aggressive) on finasteride (Thompson 2003), producing a class label warning (Proscar label). Bias-adjusted reanalyses by the same SWOG cancer research group attribute much of the excess to easier biopsy detection in smaller glands (Redman 2008), and 18-year survival after a prostate cancer diagnosis did not differ (Thompson 2013). Net: a small true excess cannot be excluded, but detection bias explains much of it.
Magnitude: Gleason 8–10 cancer in 1.8% vs 1.1% with placebo (Propecia label); at 18 years, high-grade cancer in 3.5% vs 3.0% (RR 1.17; 95% CI 1.00–1.37) (Thompson 2013).
Gynecomastia (Male Breast Enlargement) ⚠️ Conflicted
Altered androgen–estrogen balance can enlarge or sensitize male breast tissue. Label data from the manufacturer-sponsored PLESS trial (McConnell 1998) show excess breast enlargement and tenderness at 5 mg (Propecia label), and an independent UK cohort found more gynecomastia with 5α-reductase inhibitors (Hagberg 2017). In the placebo-controlled 1 mg trials, breast tenderness and enlargement did not differ from placebo (Propecia label). Male breast cancer was not increased in a meta-analysis of four observational studies (Wang 2018). Net: a real excess at 5 mg, not shown in the 1 mg trials.
Magnitude: Breast enlargement in 0.5% vs 0.1% with placebo in year 1 and 1.8% vs 1.1% in years 2–4 (Propecia label); gynecomastia incidence rate ratio (ratio of new-case rates) 3.55 vs unexposed men (95% CI 3.05–4.14) (Hagberg 2017).
Reduced Ejaculate Volume and Semen Quality ⚠️ Conflicted
Because seminal secretion depends on DHT, finasteride at 5 mg lowers ejaculate volume and, in some men, sperm count and motility. A one-year RCT in healthy men found mild, apparently reversible decreases with 5 mg (Amory 2007), and the label lists postmarketing male infertility and hematospermia (blood in semen) (Propecia label). A Merck-sponsored 48-week RCT of 1 mg in 181 young men found no significant effect on sperm or ejaculate volume (Overstreet 1999). Net: a mild 5 mg effect, relevant mainly to men planning conception, not shown at 1 mg.
Magnitude: At 1 mg, median ejaculate volume differed from placebo by −0.03 mL (1%; 90% CI −10.4% to 13.1%), not significant (Overstreet 1999); at 5 mg, median ejaculate volume fell 0.6 mL (22.1%) over 24 weeks in healthy volunteers, and the label gives no placebo figure (Proscar label).
Depression, Self-Harm and Suicidal Ideation ⚠️ Conflicted
Reduced neuroactive steroids are the proposed mechanism. An independent Canadian cohort found more depression and early self-harm in new users (Welk 2017) and a Swedish cohort more depression (Garcia-Argibay 2022), Medicare follow-up of the randomized PCPT arms found more depression claims (Unger 2016), a meta-analysis by Pompili’s group found higher depression odds (Pompili 2021), and the EMA confirmed suicidal ideation as a side effect (EMA referral). A meta-analysis by Uleri’s group found no significant association (Uleri 2024). Net: a modest real signal is likely, though its size remains uncertain.
Magnitude: Depression HR 1.94 (95% CI 1.73–2.16) in the first 18 months, with absolute excesses of 237 depression and 17 self-harm events per 100,000 patient-years versus matched non-users (Welk 2017); depression HR 1.10 (95% CI 1.01–1.19) versus placebo in randomized-arm follow-up (Unger 2016); pooled depression adjusted HR 1.30 (95% CI 0.85–2.00) (Uleri 2024).
Floppy Iris During Cataract Surgery
Intraoperative floppy iris syndrome (an iris that billows and constricts during cataract surgery, raising the chance of surgical complications) is best known with tamsulosin. Finasteride use was independently associated with it in prospective cohorts by Chatziralli’s Athens group (Chatziralli 2016) and Kaczmarek’s Warsaw group (Kaczmarek 2019), and in a 38-study meta-analysis (Christou 2022). The mechanism is unclear, and the risk matters mainly to older men facing cataract surgery.
Magnitude: Floppy iris OR 4.60 (95% CI 1.97–10.73) with finasteride versus non-use, pooled from observational studies; the meta-analysis reports no absolute rates (Christou 2022).
Low 🟥
Persistent Symptoms After Stopping (Post-Finasteride Syndrome)
Some men report sexual, cognitive and mood symptoms persisting after discontinuation, possibly from lasting neuroactive-steroid changes; the label lists persistent sexual dysfunction (Propecia label). Evidence is weak: a former-user survey with community controls (Irwig 2012) and a cohort without unexposed controls (Kiguradze 2017); a review calls it disputed (Cilio 2025).
Magnitude: 0.8% of men aged 16–42 taking ≤1.25 mg developed erectile dysfunction lasting ≥90 days after stopping (no control group; risk was 4.9-fold higher with more than 205 days of exposure than with shorter exposure) (Kiguradze 2017).
New-Onset Type 2 Diabetes ⚠️ Conflicted
UK and Taiwanese cohorts found more incident type 2 diabetes with finasteride than with tamsulosin (Wei 2019), but Medicare follow-up of the randomized PCPT arms found no difference in diabetes (Unger 2016). The mechanism is uncertain. Net: an observational signal that randomized follow-up did not reproduce.
Magnitude: 76.6 vs 60.3 events per 10,000 person-years with tamsulosin (adjusted HR 1.26; 95% CI 1.10–1.45) (Wei 2019).
Dementia Diagnosis
Cohorts found more dementia diagnoses soon after starting 5α-reductase inhibitors, but the excess faded with longer use (Welk 2017; Garcia-Argibay 2022). Authors attribute this to earlier detection in men seeing clinicians for urinary symptoms.
Magnitude: Dementia HR 2.18 (95% CI 2.01–2.35) in year 1 versus matched non-users, falling to 1.06 (95% CI 0.98–1.14) with the longest exposure (Welk 2017).
Masked PSA and Delayed Cancer Detection
Finasteride lowers PSA by about half, per a pharmacology review (Steiner 1996), so unadjusted results can hide a rising cancer signal. The label calls for evaluating any confirmed rise from the lowest on-drug value (Proscar label). Evidence is indirect: no trial has measured missed or delayed diagnoses.
Magnitude: PSA falls about 50% on 5 mg; on 1 mg, mean PSA fell from 0.7 to 0.5 ng/mL over 12 months, and the label gives no placebo comparison (Proscar label; Propecia label).
Hypersensitivity Reactions and Testicular Pain ⚠️ Conflicted
Postmarketing reports include rash, itching, hives, angioedema (deep swelling of lips, tongue or throat) and testicular pain. In the 1 mg trials (Kaufman 1998), rates did not differ from placebo (Propecia label). Net: rare reactions recognized from spontaneous reports, not trials.
Magnitude: Not quantified in available studies. The placebo-controlled trials found no excess, and voluntary postmarketing reports cannot yield incidence rates.
Genital Malformation in an Exposed Male Fetus
Contraindicated in pregnancy: blocking DHT caused male fetal genital abnormalities in rats and monkeys (Propecia label). Evidence is indirect: the human data come from inherited 5α-reductase deficiency, which causes incomplete male genital development before birth (Imperato-McGinley 1974), not from drug-exposed pregnancies.
Magnitude: Not quantified in available studies. No series of finasteride-exposed pregnancies has reported outcome rates; the available figures come from animal studies.
Speculative 🟨
No risk is graded Speculative: every listed risk has human data, at minimum postmarketing reports, uncontrolled cohorts or the indirect evidence of inherited 5α-reductase deficiency.
Risk-Modifying Factors
- Genetic variation: No validated genetic marker predicts side effects; a review calls genetic predisposition a proposed but unproven factor in persistent post-finasteride symptoms (Cilio 2025).
- Younger age and hair-loss use: Disproportionate suicidality reports in the WHO (World Health Organization) safety database were concentrated in men under 45 using finasteride for hair loss, not in older men with BPH (Nguyen 2021).
- Older age: Plasma half-life lengthens to about 8 hours after age 70 without dose change (Propecia label); diabetes and dementia-diagnosis signals come from cohorts of older men (Wei 2019; Welk 2017).
- Prior depression: The EMA advises stopping 1 mg finasteride if mood changes occur (EMA referral); a psychiatric history is a plausible, unquantified risk amplifier.
- Baseline glucose status: Cohort authors suggest additional glucose monitoring for men with other type 2 diabetes risk factors (Wei 2019).
- Liver impairment: Finasteride is extensively metabolized in the liver, its pharmacokinetics (how the body absorbs, distributes and clears a drug) in liver impairment are unstudied, and the label advises caution (Propecia label).
- NSAID co-use: In men without prostate disease, combining NSAID (nonsteroidal anti-inflammatory drug) use with more than 208 days of exposure was linked to 4.8-fold higher persistent erectile dysfunction risk (Kiguradze 2017).
- Sex: Women of reproductive potential carry the fetal risk, and finasteride is contraindicated in pregnancy (Propecia label).
- Baseline semen quality: Men with borderline fertility may be more affected by the mild semen reductions seen in trials (Amory 2007); this is inferred, not studied.
Key Interactions & Contraindications
Documented interactions:
- Doxazosin (an alpha-blocker): No pharmacokinetic interaction in a Pfizer-sponsored study (Vashi 1998); combination reduced BPH progression more than either drug (McConnell 2003). Consequence: additive urinary benefit, plus doxazosin’s dizziness on standing. Mitigation: standard gradual doxazosin dose titration.
- Terazosin: Finasteride exposure rose with terazosin in one study (Vashi 1998) but not in an Abbott-sponsored study (Samara 1996). Consequence: clinical significance undetermined. Mitigation: no dose change described.
- Tamsulosin: No clinically significant pharmacokinetic interaction in a crossover study sponsored by MSD, the finasteride manufacturer, (Chu 2015). Consequence: none identified.
- Warfarin, digoxin, propranolol, theophylline, antipyrine: No clinically meaningful interactions in human testing (Propecia label). Consequence: none; routine monitoring of these drugs continues.
- Testosterone (testosterone enanthate, testosterone cypionate): Finasteride prevented testosterone-induced prostate growth and blunted the PSA rise without reducing muscle, fat-loss or bone effects (Borst 2014; Amory 2004). Consequence: lower prostate and PSA response. Mitigation: re-baselining PSA on combined therapy.
- Oral testosterone: Finasteride more than doubled serum testosterone exposure with oral testosterone in oil (Amory 2006), but did not change levels with oral testosterone undecanoate (Roth 2011). Consequence: higher testosterone levels with some oral forms. Mitigation: checking testosterone after adding finasteride.
- NSAIDs (ibuprofen, naproxen): Long co-use was linked to higher persistent erectile dysfunction risk in a record-based cohort (Kiguradze 2017); trials found no adverse interaction with NSAIDs, acetaminophen or aspirin (Propecia label). Mitigation: limiting chronic NSAID use.
- Glucocorticoids (steroid anti-inflammatories, e.g., prednisolone): In a 7-day randomized study in healthy men, adding finasteride or dutasteride to prednisolone 10 mg raised prednisolone levels and worsened insulin resistance (Othonos 2020). Consequence: stronger glucocorticoid metabolic effects. Mitigation: closer glucose monitoring or glucocorticoid dose review.
- PSA blood test: Finasteride lowers PSA by about 50% (Proscar label). Consequence: unadjusted results understate cancer risk. Mitigation: evaluating any confirmed rise from the lowest on-drug value.
- Tadalafil (a PDE5 inhibitor, an erectile dysfunction drug): In a 695-man placebo-controlled trial sponsored by its manufacturer Lilly, tadalafil 5 mg added to finasteride 5 mg improved erectile and sexual function with few sexual adverse events (Glina 2015). Consequence: partial offset of finasteride’s sexual effects.
- St John’s wort (Hypericum perforatum, a CYP3A4-inducing herbal supplement): In 12 healthy men, 14 days of St John’s wort lowered finasteride peak level by 58% and exposure by 34% (Lundahl 2009). Consequence: possibly weaker hair or prostate response. Mitigation: avoiding concurrent use or reassessing response.
- Topical minoxidil: A meta-analysis of five RCTs found the combination improved photographic hair scores versus either drug alone, with similar adverse events (Chen 2020). Consequence: additive hair benefit without added harm in trials.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Other 5α-reductase inhibitors (dutasteride): Duplicated mechanism; consequence: additive DHT suppression and sexual side effects without established added benefit. Mitigation: avoiding unintended duplicate therapy.
- Strong CYP3A4 inhibitors (ketoconazole tablets, itraconazole, ritonavir, grapefruit juice): Shared CYP3A4 metabolism could raise finasteride levels; consequence: possibly more DHT-related side effects, likely small given finasteride’s wide dose tolerance. Mitigation: none usually needed.
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Faster CYP3A4 metabolism could lower finasteride levels; consequence: weaker hair or prostate response. Mitigation: reassessing response after starting an inducer.
- Saw palmetto (Serenoa repens), beta-sitosterol, pumpkin seed oil: Proposed weak 5α-reductase inhibition; consequence: additive DHT lowering and overlapping sexual effects with little added benefit. Mitigation: avoiding combined use without a defined goal.
- SSRIs (selective serotonin reuptake inhibitors, a common antidepressant class, e.g., sertraline, paroxetine) and spironolactone: Independent sexual and mood effects; consequence: additive sexual dysfunction and harder attribution of mood changes. Mitigation: tracking sexual-function and mood scores after starting either.
Populations who should avoid Finasteride:
- Women who are or may become pregnant: Contraindicated because of genital abnormality risk in a male fetus; the label also warns them against handling crushed or broken tablets (Propecia label).
- Children and adolescents: Not indicated; safety and effectiveness not established (Propecia label).
- Hypersensitivity to finasteride or tablet components: Contraindicated (Proscar label).
- Men with current depression or suicidal thoughts: Inferred from the EMA instruction to stop 1 mg finasteride when mood changes occur (EMA referral); no study tested starting the drug in this group.
- Men seeking conception soon with poor baseline semen quality: Inferred from mild, apparently reversible semen reductions (Amory 2007) and postmarketing infertility reports (Propecia label); no study tested this group.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- PSA re-baselining: PSA is measured before starting and after about 6 months; any confirmed rise from the lowest on-drug value is a signal for evaluation (Proscar label). Mitigates delayed prostate cancer detection.
- Mood checkpoint: Mood is screened at each visit with the PHQ-9 (a 9-item depression questionnaire); the EMA instructs stopping 1 mg finasteride and seeking medical advice if depressed mood or suicidal thoughts appear (EMA referral). Mitigates depression and suicidality.
- Sexual function tracking: A baseline IIEF-5 (a 5-item erectile function questionnaire) score is repeated at 3 and 6 months; a sustained drop prompts dose review, a topical form or stopping. Mitigates ongoing sexual dysfunction.
- Lower systemic exposure: Topical finasteride gave over 100-fold lower peak blood levels and less serum DHT reduction (34.5% vs 55.6%) than oral, with similar hair counts (Piraccini 2022). Mitigates systemic sexual and mood effects.
- Pregnancy exposure control: Tablets are kept intact and away from pregnant partners, and skin touched by crushed tablets is washed with soap and water (Propecia label). Mitigates fetal genital malformation risk.
- Conception planning: A semen analysis clarifies fertility status; semen changes appeared reversible after stopping in a one-year trial (Amory 2007), so pausing about 3–6 months before conception is common practice. Mitigates reduced semen quality.
- Metabolic check: HbA1c (average blood glucose over about 3 months) or fasting glucose is checked annually, more often with other diabetes risk factors (Wei 2019). Mitigates undetected new-onset type 2 diabetes.
- Breast changes: The label calls for prompt reporting of breast lumps, pain or nipple discharge (Proscar label). Mitigates progressive gynecomastia and missed male breast cancer.
- Cataract surgery notice: The eye surgeon is told about current finasteride use before cataract surgery, so iris-stabilizing measures can be planned (Christou 2022). Mitigates floppy-iris surgical complications.
- Approved rather than compounded topicals: Compounded topical finasteride lacks FDA-approved labeling, has generated adverse event reports, and has no protective coating (FDA topical finasteride alert). Mitigates unregulated dosing and transfer to women.
Therapeutic Protocol
Timing, titration and cycling parameters below without a citation reflect common practice.
- Prostate enlargement: 5 mg once daily, alone or with doxazosin (Proscar label); retention and surgery benefits accrue over years (McConnell 1998).
- Male pattern hair loss: 1 mg once daily (Propecia label), often paired with topical minoxidil, per a meta-analysis (Chen 2020); Peter Attia’s urologist guest discusses it alongside post-finasteride syndrome and PSA (Attia podcast #273).
- Prostate cancer risk reduction (off-label): The PCPT regimen was 5 mg daily for 7 years in men 55 or older with PSA ≤3.0 ng/mL (Thompson 2003); not approved for this use (Proscar label).
- Topical alternative: A skin spray is authorized in the European Union (EU) for early hair loss (EMA referral); a phase III trial showed oral-like hair counts with far lower systemic exposure (Piraccini 2022); no topical form is FDA-approved (FDA alert).
- Lower or intermittent oral dosing: Some users reduce dose to limit side effects; little DHT suppression occurs below 0.5 mg daily, per a pharmacology review (Steiner 1996), and no outcome trial supports intermittent dosing.
- With testosterone therapy: Trials paired 5 mg daily with testosterone enanthate 125 mg weekly (Borst 2014) or 200 mg every 2 weeks (Amory 2004) to limit prostate growth.
- Time of day: Any consistent time, with or without meals; food does not alter bioavailability (Propecia label).
- Half-life: Plasma half-life is 5–6 hours (8 hours over age 70), but enzyme inhibition persists far longer (Propecia label).
- Single versus split dosing: A single daily dose is standard, because one dose suppresses DHT for up to 4 days, per a pharmacology review (Steiner 1996); splitting offers no known advantage.
- Genetics: No genotype-guided dosing exists; SRD5A2 and other steroid-gene variants remain research-stage predictors of response, per a review (Hulin-Curtis 2010).
- Sex: Approved uses are for men only; in women, efficacy is shown for hirsutism in a network meta-analysis (Barrionuevo 2018) but not postmenopausal hair loss (Price 2000), and use in pregnancy is contraindicated (Propecia label).
- Age: No dose adjustment is needed for older men (Propecia label).
- Baseline biomarkers: Baseline PSA anchors later interpretation; prevention benefit was seen with baseline PSA below 4.0 ng/mL, per a Cochrane review (Wilt 2008).
- Pre-existing conditions: No adjustment for kidney impairment; caution in liver impairment (Propecia label); closer mood follow-up with a depression history is inferred from the EMA instruction to stop 1 mg use if mood changes occur (EMA referral).
Discontinuation & Cycling
- Duration: Benefits require continued use; hair gains reverse within 12 months of stopping (Propecia label), and DHT rises again after discontinuation, probably bringing urinary symptoms back, per a pharmacology review (Steiner 1996).
- Finite prevention course: After the 7-year PCPT course ended, the lower prostate cancer risk held through 16 years without later excess (Unger 2018).
- Withdrawal effects: No physiological withdrawal syndrome is described; some men report sexual, cognitive or mood symptoms that persist after stopping (Propecia label; review: Cilio 2025).
- Tapering: No tapering protocol has been studied; stopping at once is standard.
- Cycling: Cycling is not supported for efficacy; DHT recovers within days of stopping and hair or prostate benefit is gradually lost, and no trial has tested intermittent courses.
- PSA after stopping: PSA drifts back toward pre-treatment levels, so a new PSA baseline about 6 months after stopping is common practice.
Sourcing and Quality
- Formulations: Film-coated 1 mg (Propecia) and 5 mg (Proscar) tablets from Organon, plus FDA-approved generics; the coating prevents skin contact unless tablets are broken (Propecia label).
- Generics: FDA-approved generics from licensed pharmacies meet bioequivalence (same absorption as the brand) standards (FDA generic drug facts); supplement-style third-party testing is not relevant for regulated prescription products.
- Tablet splitting: Quartering 5 mg tablets to approximate 1.25 mg is a common cost-saving practice, but broken tablets expose pregnant women to the drug (Propecia label).
- Compounded topicals: Sold by compounders and telemedicine platforms without FDA-approved labeling; FDA received 32 adverse event reports from 2019 to 2024 (FDA topical finasteride alert).
- Regulated topical: In the EU, an authorized finasteride skin spray offers a quality-controlled topical option (EMA referral).
- Online sellers: Unlicensed websites selling finasteride without prescription carry counterfeit and dosing risks; licensed pharmacies are the reliable source.
Practical Considerations
- Time to effect: Hair benefit needs 3 or more months of daily use (Propecia label); BPH symptom benefit over placebo appears mainly in trials longer than one year, per a Cochrane review (Tacklind 2010).
- Common pitfalls: Not telling clinicians about finasteride when PSA is tested; stopping and losing hair gains within a year; handling crushed tablets near pregnant partners; attributing every symptom to the drug, or dismissing persistent ones.
- Regulatory status: Prescription-only; FDA-approved for BPH, not for prostate cancer prevention (Proscar label), and for male pattern hair loss in men (Propecia label); EU labels list suicidal ideation as a side effect (EMA referral).
- Guideline context: The 2026 AUA (American Urological Association) guideline addresses 5α-reductase inhibitors, post-finasteride syndrome and PSA effects (Goueli 2026); AUA members earn revenue from BPH procedures, which finasteride reduces.
- Payer incentives: Generic finasteride costs far less than BPH procedures, giving insurers and national health systems a structural incentive to favor drug therapy over surgery, a potential bias in guideline formation and research funding.
- Cost and access: Generic tablets are inexpensive and widely available by prescription, including through telemedicine.
Interaction with Foundational Habits
- Sleep: Indirect, potentially disruptive. Finasteride reduces neuroactive steroids (Godar 2019), and insomnia appears in FDA-received topical-product reports (FDA topical finasteride alert). A U.S. Department of Veterans Affairs (VA) trial is testing finasteride for breathing instability in older adults with sleep apnea (NCT02703220). Tracking sleep quality after starting is practical.
- Nutrition: No direct interaction; food does not change absorption (Propecia label). Indirectly, the diabetes signal (Wei 2019) favors a glucose-controlling diet; saw palmetto and pumpkin seed supplements overlap mechanistically and add little.
- Exercise: None to neutral. Finasteride raises testosterone about 15% (Propecia label) and did not blunt testosterone-driven strength or lean-mass gains in older men (Borst 2014). No evidence shows impaired hypertrophy (muscle growth); workout timing is irrelevant.
- Stress management: Possibly blunting. In rats, finasteride reduced stress coping and altered HPA axis (hypothalamic–pituitary–adrenal stress-hormone system) signaling (Godar 2019); human depression signals (Welk 2017) support regular mood checks and consistent stress-management practice.
Monitoring Protocol & Defining Success
Baseline testing before the first dose establishes reference points that finasteride itself will shift: PSA, which falls by about half, plus sexual-function and mood questionnaires and, for prostate users, the IPSS (International Prostate Symptom Score, a 0–35 urinary symptom questionnaire). Men with diabetes risk factors add HbA1c, men planning conception add a semen analysis, and hair users take standardized scalp photographs.
Ongoing monitoring follows a cadence of 3 months, 6 months, then every 12 months: questionnaires at each visit, PSA re-baselined at 6 months and then checked annually, and HbA1c annually. Hair response is judged on photographs at 6 and 12 months, since benefit needs at least 3 months to appear (Propecia label).
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| PSA | 0–4.0 ng/mL (standard reference range); on finasteride, track change from the lowest on-treatment value | Safety check: a confirmed rise prompts evaluation | Falls about 50% on 5 mg (Proscar label); test before starting and at 6 months; ejaculation within 48 hours before testing can raise PSA |
| Serum DHT | Laboratory reference range, roughly 30–85 ng/dL in men, varying by assay (standard reference range); track percentage suppression from own baseline | Expected to change: confirms drug effect | About 65% suppression at 1 mg (Propecia label); LC-MS/MS (liquid chromatography–tandem mass spectrometry) assays are most accurate |
| Total testosterone | Laboratory reference range, roughly 264–916 ng/dL in men (standard reference range) | Expected to change: rises about 15% | Morning sample; rise stays within physiological range (Propecia label) |
| HbA1c | 4.0–5.6% (standard reference range) | Safety check: diabetes signal | No fasting needed; annual (Wei 2019) |
| IIEF-5 score | No established target; track change from own baseline | Safety check: a sustained fall prompts dose review | Score range 5–25; repeat at 3 and 6 months, then annually |
| PHQ-9 score | No established target; track change from own baseline | Safety check: new depression or suicidal thoughts stop 1 mg use | EMA: stop 1 mg use if mood changes occur (EMA referral); item 9 asks about self-harm thoughts |
| IPSS (prostate users) | No established target; track change from own baseline | Expected to change: improvement | A 4-point change is clinically meaningful, per a Cochrane review (Tacklind 2010) |
| Semen analysis (if planning conception) | Sperm concentration ≥16 million/mL (standard reference range, WHO 2021 semen manual lower reference limit) | Safety check: reduced quality prompts pausing | 2–7 days of abstinence before sampling; changes appeared reversible after stopping (Amory 2007) |
Qualitative markers:
- Hair shedding and density on standardized photographs
- Libido, erection quality and ejaculate volume
- Mood, motivation and emotional flatness
- Sleep quality and mental clarity
- Urinary stream and nighttime urination (prostate users)
- Breast tenderness or enlargement
Emerging Research
- Testosterone with or without finasteride after spinal cord injury: VA phase 2/3 RCT of 300 men; primary endpoint lower-limb fat-free mass (NCT07742553); not yet recruiting. Equal muscle gains with less prostate growth would strengthen finasteride as a safeguard during TRT; a null difference confirms neutrality; a muscle penalty would weaken that case.
- Finasteride for sleep apnea in older adults: VA phase 4 crossover trial of 100 adults testing oxygen, acetazolamide and finasteride, each against its own control, on breathing instability (apneic threshold) (NCT02703220); recruiting, completion December 2027. A positive result adds a sleep-related benefit for older men; a null result keeps benefits confined to prostate and hair.
- Predicting non-response in BPH: Beth Israel Deaconess study of 120 men testing whether type 2 5α-reductase expression and MRI-detected (magnetic resonance imaging) inflammation predict symptom-score response (NCT04288427); recruiting, primary completion June 2026 passed, no results posted. Positive: likely responders become identifiable; null: response stays unpredictable.
- Finasteride plus tamsulosin: Il-Yang phase 3 RCT of 660 men comparing combination with each monotherapy on IPSS (NCT07870759); not yet recruiting. A positive result supports combination use for urinary symptoms; a null result favors monotherapy and less side-effect exposure.
- Persistent symptom mechanisms: Reviews call for controlled studies of neurobiological and genetic mechanisms (Cilio 2025); evidence so far is a small survey with community controls (Irwig 2012). Confirmation of a lasting harm would weaken the case; a low, nocebo-driven (caused by negative expectation) incidence would strengthen it.
- Long-term prostate cancer mortality: PCPT mortality shows a non-significant reduction (Goodman 2019); further registry linkage, as with Medicare follow-up (Unger 2018), could confirm a survival benefit or settle on no effect.
- Mood and metabolic signals: Depression findings conflict between cohorts (Garcia-Argibay 2022) and pooled analysis (Uleri 2024), as do diabetes findings (Wei 2019 vs Unger 2016). Randomized or target-trial analyses (observational analyses designed to mimic a randomized trial) could confirm either harm or show none.
Conclusion
Finasteride is an inexpensive, long-studied prescription tablet that lowers the hormone driving prostate growth and pattern hair loss. For health-focused adults, its clearest benefits are fewer complications from an enlarged prostate and slower hair loss, along with fewer prostate cancer diagnoses, mostly of slow-growing tumors, in one large prevention study. Whether it lengthens life is unproven: long follow-up shows neither a clear survival gain nor the survival harm once feared from an early signal of more aggressive tumors.
The best-documented costs are sexual side effects in a minority of users, breast tissue changes, lower semen volume, and lower readings on the prostate cancer blood test, which then require careful interpretation. More contested are mood effects, a possible diabetes signal, and reports of symptoms that persist after stopping; this evidence comes largely from studies that watched users without random assignment or had no comparison group, although European regulators now list suicidal thoughts as a side effect.
The evidence base is large but uneven. Much of the hair and prostate-symptom research was funded by the original manufacturer, while the major cancer prevention study was publicly funded; urologists’ income from prostate procedures and insurers’ savings compared with surgery add opposing financial interests. Benefits fade once the drug is stopped. For men already tracking prostate markers, mood and sexual function, finasteride offers well-documented prostate and hair benefits whose overall value depends on how uncertain but potentially lasting harms are weighed against them.